290 related articles for article (PubMed ID: 19318452)
1. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects.
Li H; Bao Y; Xu A; Pan X; Lu J; Wu H; Lu H; Xiang K; Jia W
J Clin Endocrinol Metab; 2009 Jun; 94(6):2151-6. PubMed ID: 19318452
[TBL] [Abstract][Full Text] [Related]
2. Dynamic change of serum FGF21 levels in response to glucose challenge in human.
Lin Z; Gong Q; Wu C; Yu J; Lu T; Pan X; Lin S; Li X
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1224-8. PubMed ID: 22539584
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
[TBL] [Abstract][Full Text] [Related]
4. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation.
Strączkowski M; Karczewska-Kupczewska M; Adamska A; Otziomek E; Kowalska I; Nikołajuk A
Int J Obes (Lond); 2013 Oct; 37(10):1386-90. PubMed ID: 23419601
[TBL] [Abstract][Full Text] [Related]
5. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins.
Tyynismaa H; Raivio T; Hakkarainen A; Ortega-Alonso A; Lundbom N; Kaprio J; Rissanen A; Suomalainen A; Pietiläinen KH
J Clin Endocrinol Metab; 2011 Feb; 96(2):E351-5. PubMed ID: 21123446
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids.
Thamer C; Tschritter O; Haap M; Shirkavand F; Machann J; Fritsche A; Schick F; Häring H; Stumvoll M
Horm Metab Res; 2005 Apr; 37(4):246-51. PubMed ID: 15952086
[TBL] [Abstract][Full Text] [Related]
7. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.
Chavez AO; Molina-Carrion M; Abdul-Ghani MA; Folli F; Defronzo RA; Tripathy D
Diabetes Care; 2009 Aug; 32(8):1542-6. PubMed ID: 19487637
[TBL] [Abstract][Full Text] [Related]
8. Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance.
Lui DTW; Lee CH; Chau VWK; Fong CHY; Yeung KMY; Lam JKY; Lee ACH; Chow WS; Tan KCB; Woo YC; Lam KSL
J Endocrinol Invest; 2021 Mar; 44(3):523-530. PubMed ID: 32602078
[TBL] [Abstract][Full Text] [Related]
9. Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner.
Zhang J; Li H; Bai N; Xu Y; Song Q; Zhang L; Wu G; Chen S; Hou X; Wang C; Wei L; Xu A; Fang Q; Jia W
J Endocrinol Invest; 2019 Sep; 42(9):1019-1027. PubMed ID: 30852757
[TBL] [Abstract][Full Text] [Related]
10. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
Iglesias P; Selgas R; Romero S; Díez JJ
Eur J Endocrinol; 2012 Sep; 167(3):301-9. PubMed ID: 22740503
[TBL] [Abstract][Full Text] [Related]
11. Metabolic characteristics of subjects with normal glucose tolerance and 1-h hyperglycaemia.
Qian L; Fu X; Xu L; Zheng S; Zhou W; Wang X; Gu Y; Lin F; Luo M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):575-9. PubMed ID: 18248638
[TBL] [Abstract][Full Text] [Related]
12. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose.
Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
J Clin Endocrinol Metab; 2012 Dec; 97(12):4717-23. PubMed ID: 23066121
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
14. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors.
Chow WS; Xu A; Woo YC; Tso AW; Cheung SC; Fong CH; Tse HF; Chau MT; Cheung BM; Lam KS
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2454-9. PubMed ID: 23887638
[TBL] [Abstract][Full Text] [Related]
15. Impaired insulin sensitivity is accompanied by disturbances in skeletal muscle fatty acid handling in subjects with impaired glucose metabolism.
Moors CC; van der Zijl NJ; Diamant M; Blaak EE; Goossens GH
Int J Obes (Lond); 2012 May; 36(5):709-17. PubMed ID: 21712806
[TBL] [Abstract][Full Text] [Related]
16. Serum fibroblast growth factor 21 in overweight and obese Thai children and adolescents: its relation to glucose metabolism and its change after glucose loading.
Korwutthikulrangsri M; Mahachoklertwattana P; Chanprasertyothin S; Pongratanakul S; Poomthavorn P
Clin Endocrinol (Oxf); 2015 Dec; 83(6):820-7. PubMed ID: 25929297
[TBL] [Abstract][Full Text] [Related]
17. Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels.
Fang Q; Li H; Song Q; Yang W; Hou X; Ma X; Lu J; Xu A; Jia W
Diabetes Care; 2013 Sep; 36(9):2810-4. PubMed ID: 23628619
[TBL] [Abstract][Full Text] [Related]
18. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques.
An SY; Lee MS; Yi SA; Ha ES; Han SJ; Kim HJ; Kim DJ; Lee KW
Diabetes Res Clin Pract; 2012 May; 96(2):196-203. PubMed ID: 22293928
[TBL] [Abstract][Full Text] [Related]
19. Serum gamma-glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation.
Bianchi C; Penno G; Crisci I; Daniele G; Agostini A; Del Prato S; Miccoli R
Diabetes Metab Res Rev; 2010 Mar; 26(3):181-6. PubMed ID: 20186999
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients.
Miyazaki Y; Pipek R; Mandarino LJ; DeFronzo RA
Int J Obes Relat Metab Disord; 2003 Jan; 27(1):88-94. PubMed ID: 12532159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
